Darbie Maccubbin - Concepedia

Author

Darbie Maccubbin

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

D L Maccubbin, D Maccubbin, D. Maccubbin, D.L. Maccubbin, Darbie L Maccubbin, Darbie L. MacCubbin, Darbie L. Maccubbin, Darbie MacCubbin, Darbie Maccubbin

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Roswell Park Comprehensive Cancer Center Louisville Metabolic and Atherosclerosis Research Center Grace (United States)National Clinical Research

About

Darbie Maccubbin is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	26	971
2	Allergy	2	2	106
3	Health Sciences	1	1	13
4	Public Health	1	1	41
5	Anesthesia	1	1	14

Darbie Maccubbin

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin Evan A. Stein, Steen Stender, Pedro Mata, American Heart Journal Lipid DisorderCardiovascular DiseaseMedicineHyperlipidemiaPharmacotherapy	2004	160
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia Darbie Maccubbin, Harold Bays, Anders Olsson, International Journal of Clinical Practice	2008	113
Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome Leon A. Simons, Melvin J. Tonkon, L. Masana, Current Medical Research and Opinion	2004	89
MHC-restricted cytotoxic response of chicken T cells: expression, augmentation, and clonal characterization. Darbie Maccubbin, Louis W. Schierman The Journal of Immunology	1986	87
Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease Darbie Maccubbin, Michael J. Koren, Michael Davidson, The American Journal of Cardiology Ischemic Cardiovascular DiseaseCardiovascular DiseasePharmacologyMedicineAtherosclerosis	2009	71
Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. M. Jane Ehrke, Darbie Maccubbin, Kazuo Ryoyama, PubMed ImmunotoxicologyImmunologyCell DeathImmunologic MechanismImmunotherapy	1986	68
Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha. Srđan Verstovšek, Darbie Maccubbin, M. Jane Ehrke, PubMed Tumoricidal ActivationImmunologyImmune RegulationPathologyCell Death	1992	66
Adriamycin-induced modulation of host defenses in tumor-bearing mice. Darbie Maccubbin, Kajsa Wing, Kenneth Mace, PubMed Functional Immune SystemCancer ImmunosurveillanceOncologyDrug TargetingMedicine	1992	65
Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Kenneth Mace, M. Jane Ehrke, Kazuyoshi Hori, PubMed Macrophage ActivationImmunologyCell DeathPathologyImmunologic Mechanism	1988	63
Hypophosphatemic Effect of Niacin in Patients without Renal Failure Darbie Maccubbin, Diane Tipping, Olga Kuznetsova, Clinical Journal of the American Society of Nephrology	2010	55

Page 1